

MEDICAL POLICY



POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Original Issue Date (Created):	July 26, 2004
Most Recent Review Date (Revised):	September 24, 2013
Effective Date:	November 1, 2013

I. POLICY

Low-level laser therapy is considered **investigational** for all indications including but not limited to treatment of carpal tunnel syndrome. There is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

High power Class IV therapeutic laser light therapy or similar therapeutic laser light therapy is considered **investigational** for all conditions, as there is insufficient evidence to support a conclusion concerning the health outcomes or benefits associated with this procedure.

Cross-reference

MP-1.094 Skin Contact Monochromatic Infrared Energy for the Treatment of Cutaneous Ulcers, Diabetic Neuropathy, and Other Miscellaneous Musculoskeletal Conditions

II. PRODUCT VARIATIONS

[N] = No product variation, policy applies as stated

[Y] = Standard product coverage varies from application of this policy, see below

[N] Capital Cares 4 Kids

[N] Indemnity

[N] PPO

[N] SpecialCare

[N] HMO

[N] POS

[Y] FEP PPO*

[N] SeniorBlue

[N] SeniorBlue PPO

* For low level laser refer to FEP Medical Policy Manual MP-2.01.56 Low-Level Laser Therapy. The FEP Medical Policy manual can be found at:

<http://bluewebportal.bcbs.com/landingpagelevel3/504100?docId=23980>

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

* For High power Class IV therapeutic laser light therapy or similar therapeutic laser light therapy -- The FEP program dictates that all drugs, devices or biological products approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational. Therefore, FDA-approved drugs, devices or biological products may be assessed on the basis of medical necessity.

III. DESCRIPTION/BACKGROUND

Low-Level Laser Therapy

Low-level laser therapy (LLLT), also called photobiomodulation, is being evaluated to treat a variety of conditions including soft tissue injuries, tendinopathies, nerve injuries, and joint pain.

Low-level laser therapy (LLLT) refers to the use of red-beam or near-infrared lasers with a wavelength between 600 and 1,000 nm and power from 5–500 MW. (In contrast, lasers used in surgery typically use 300 W.) When applied to the skin, these lasers produce no sensation and do not burn the skin. Because of the low absorption by human skin, it is hypothesized that the laser light can penetrate deeply into the tissues where it has a photobiostimulative effect. The exact mechanism of its effect on tissue healing is unknown; hypotheses have included improved cellular repair and stimulation of the immune, lymphatic, and vascular systems. LLLT is being evaluated to treat a wide variety of conditions, including soft tissue injuries, tendinopathies, nerve injuries, and joint pain. LLLT has also been evaluated for lymphedema.

One of the disorders that LLLT has been evaluated for is the treatment of carpal tunnel syndrome. Carpal tunnel syndrome is the most common entrapment neuropathy and the most commonly performed surgery of the hand. The syndrome is related to the bony anatomy of the wrist. The carpal tunnel is bound dorsally and laterally by the carpal bones and ventrally by the transverse carpal ligament. Through this contained space run the 9 flexor tendons and the median nerve. Therefore any space-occupying lesion can compress the median nerve and produce the typical symptoms of carpal tunnel syndrome—pain, numbness, and tingling in the distribution of the median nerve. Symptoms of more severe cases include hypesthesia, clumsiness, loss of dexterity, and weakness of pinch. In the most severe cases, patients experience marked sensory loss and significant functional impairment with thenar atrophy. Mild to moderate cases of carpal tunnel syndrome are usually first treated conservatively with splinting and cessation of aggravating activities. Other conservative therapies include oral steroids, diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), and steroid injections into the carpal tunnel itself. Patients who do not respond to conservative therapy or who present with severe carpal tunnel syndrome with thenar atrophy may be considered candidates for surgical release of the carpal ligament, using either an open or endoscopic approach.

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Regulatory Status

A number of low-level lasers have received clearance for marketing from the U.S. Food and Drug Administration (FDA) for the treatment of pain. Data submitted to the FDA as part of the FDA 510(k) approval process for the MicroLight 830 Laser consisted of application of the laser over the carpal tunnel 3 times a week for 5 weeks. The labeling states that the "MicroLight 830 Laser is indicated for adjunctive used in the temporary relief of hand and wrist pain associated with Carpal Tunnel Syndrome." In 2006, the FDA provided marketing clearance for the GRT LITE™, which listed the Tuco Erchonia PL3000, the Excalibur System, the Microlight 830 Laser, and the Acculaser Pro as predicate devices. Indications of the GRT LITE for carpal tunnel syndrome are similar to the predicate devices: "adjunctive use in providing temporary relief of minor chronic pain." The LightStream™ Low Level Laser device received 510(k) marketing clearance in 2009 for adjunctive use in the temporary relief of pain associated with knee disorders with standard chiropractic practice. A number of clinical trials of LLLT are underway in the United States, including studies of wound healing.

High power Class IV Therapeutic Laser Light Therapy

U. S. Food and Drug Administration (FDA-Cleared) High Power Class IV therapeutic laser light therapy produces 7500 milliwatts of continuous power. It is administered with a hand held device and is thought to provide deeper penetration over a larger surface area. Per the manufacturer, Avicenna Laser Technology, Inc.: the High Power, Class IV, therapeutic laser technology is used as a stand-alone modality to produce increased circulation, decreased inflammation, relaxation of muscle spasms and trigger points, accelerated tissue repair, and decreased pain at tissue sites previously unreachable by low-level stimulation. These are not the same as surgical lasers.

IV. DEFINITIONS

CARPAL TUNNEL SYNDROME is a condition of pain or numbness that affects some part of the median nerve distribution of the hand (the palmar side of the thumb, the index finger, the radial half of the ring finger, and the radial half of the palm) and may radiate into the arm.

EPICONDYLITIS is the inflammation of the epicondyle of the humerus and surrounding tissues.

FIBROMYALGIA is chronic and frequently difficult to manage pain in muscles and soft tissues surrounding joints.

RHEUMATOID ARTHRITIS is a chronic systemic disease marked by inflammation of multiple synovial joints.

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

TENDINITIS is an inflammation of a tendon.

TMJ SYNDROME is severe pain in and about the temporomandibular joint, made worse by chewing.

V. BENEFIT VARIATIONS

The existence of this medical policy does not mean that this service is a covered benefit under the member's contract. Benefit determinations should be based in all cases on the applicable contract language. Medical policies do not constitute a description of benefits. A member's individual or group customer benefits govern which services are covered, which are excluded, and which are subject to benefit limits and which require preauthorization. Members and providers should consult the member's benefit information or contact Capital for benefit information.

VI. DISCLAIMER

Capital's medical policies are developed to assist in administering a member's benefits, do not constitute medical advice and are subject to change. Treating providers are solely responsible for medical advice and treatment of members. Members should discuss any medical policy related to their coverage or condition with their provider and consult their benefit information to determine if the service is covered. If there is a discrepancy between this medical policy and a member's benefit information, the benefit information will govern. Capital considers the information contained in this medical policy to be proprietary and it may only be disseminated as permitted by law.

VII. REFERENCE

Low-Level Laser

Abrisham SM, Kermani-Alghoraishi M, Ghahramani R et al. Additive effects of low-level laser therapy with exercise on subacromial syndrome: a randomised, double-blind, controlled trial. Clin Rheumatol 2011; 30(10):1341-6

Alfredo PP, Bjordal JM, Dreyer SH et al. Efficacy of low level laser therapy associated with exercises in knee osteoarthritis: a randomized double-blind study. Clin Rehabil 2012; 26(6):523-33.

American Academy of Orthopaedic Surgeons. Clinical practice guideline on the treatment of carpal tunnel syndrome. 2008. [Website]: <http://www.aaos.org/research/guidelines/CTSTreatmentGuideline.pdf>

Accessed July 31, 2013.

Ay S, Dogan SK, Evcik D. Is low-level laser therapy effective in acute or chronic low back pain? Clin Rheumatol 2010; 29(8):905-10.

Bal A, Eksioglu E, Gurcay E et al. Low-level laser therapy in subacromial impingement syndrome. Photomed Laser Surg 2009; 27(1):31-6.

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Bjordal JM, Lopes-Martins RA, Joensen J et al. A systematic review with procedural assessments and meta-analysis of low level laser therapy in lateral elbow tendinopathy (tennis elbow). BMC Musculoskelet Disord 2008; 9:75.

Bjordal JM, Johnson MI, Lopes-Martins RA et al. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. BMC Musculoskelet Disord 2007; 8:51

Bjordal JM, Lopes-Martins RA, Joensen J et al. A systematic review with procedural assessments and meta-analysis of low level laser therapy in lateral elbow tendinopathy (tennis elbow). BMC Musculoskelet Disord 2008; 9:75.

Bjordal JM, Johnson MI, Lopes-Martins RA et al. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. BMC Musculoskelet Disord 2007; 8:51.

Blue Cross and Blue Shield Technology Evaluation Center (TEC). Low-level laser therapy for carpal tunnel syndrome and chronic neck pain. TEC Assessment 2010; Volume 25, Tab 4.

Calis HT, Berberoglu N, Calis M. Are ultrasound, laser and exercise superior to each other in the treatment of subacromial impingement syndrome? A randomized clinical trial. Eur J Phys Rehabil Med 2011

Garcia CR, Martin RL, Houck J et al. Achilles pain, stiffness, and muscle power deficits: achilles tendinitis. J Orthop Sports Phys Ther 2010; 40(9):A1-26

Carrasco TG, Guerisoli LD, Guerisoli DM et al. Evaluation of low intensity laser therapy in myofascial pain syndrome. Cranio 2009; 27(4):243-7.

Chang WD, Wu JH, Jiang JA et al. Carpal tunnel syndrome treated with a diode laser: a controlled treatment of the transverse carpal ligament. Photomed Laser Surg 2008; 26(6):551-7.

Chou R, Huffman LH. Nonpharmacologic therapies for acute and chronic low back pain: a review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Ann Intern Med 2007; 147(7):492-504

Chou R, Loeser JD, Owens DK et al. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine (Phila Pa 1976) 2009; 34(10):1066-77.

Chou R, Qaseem A, Snow V et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Ann Intern Med 2007; 147(7):478-91

Chow RT, Barnsley L, Heller GZ et al. A pilot study of low-power laser therapy in the management of chronic neck pain. J Musculoskeletal Pain 2004; 12(2):71-81

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Chow RT, Heller GZ, Barnsley L. The effect of 300 mW, 830 nm laser on chronic neck pain: a double-blind, randomized, placebo-controlled study. Pain 2006; 124(1-2):201-10

Chow RT, Johnson MI, Lopes-Martins RA et al. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials. Lancet 2009; 374(9705):1897-908.

da Cunha LA, Firoozmand LM, da Silva AP et al. Efficacy of low-level laser therapy in the treatment of temporomandibular disorder. Int Dent J 2008; 58(4):213-7.

Djavid GE, Mehrdad R, Ghasemi M et al. In chronic low back pain, low level laser therapy combined with exercise is more beneficial than exercise alone in the long term: a randomised trial. Aust J Physiother 2007; 53(3):155-60.

Dincer U, Cakar E, Kiralp MZ et al. The effectiveness of conservative treatments of carpal tunnel syndrome: splinting, ultrasound, and low-level laser therapies. Photomed Laser Surg 2009; 27(1):119-25

Dogan SK, Ay S, Evcik D. The effectiveness of low laser therapy in subacromial impingement syndrome: a randomized placebo controlled double-blind prospective study. Clinics (Sao Paulo) 2010; 65(10):1019-22.

Ekim A, Arman O, Tascioglu F et al. Effect of low level laser therapy in rheumatoid arthritis patients with carpal tunnel syndrome. Swiss Med Wkly 2007; 137(23-24): 347-52.

Emshoff R, Bösch R, Piempel E et al. Low-level laser therapy for treatment of temporomandibular joint pain: a double-blind and placebo-controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 105(4):452-6.

Evcik D, Kavuncu V, Cakir T et al. Laser therapy in the treatment of carpal tunnel syndrome: a randomized controlled trial. Photomed Laser Surg 2007; 25(1): 34-9.

Fikácková H, Dostállová T, Navrátil L et al. Effectiveness of low-level laser therapy in temporomandibular joint disorders: a placebo-controlled study. Photomed Laser Surg 2007; 25(4):297-303.

Fulop AM, Dheimer S, Deluca JR et al. A meta-analysis of the efficacy of laser phototherapy on pain relief. Clin J Pain 2010; 26(8):729-36.

Gautam AP, Fernandes DJ, Vidyasagar MS et al. Low Level Helium Neon Laser therapy for chemoradiotherapy induced oral mucositis in oral cancer patients - A randomized controlled trial. Oral Oncol 2012; 48(9):893-7.

Gautam AP, Fernandes DJ, Vidyasagar MS et al. Low level laser therapy for concurrent chemoradiotherapy induced oral mucositis in head and neck cancer patients - A triple blinded randomized controlled trial. Radiother Oncol 2012; 104(3):349-54

Hegedus B, Viharos L, Gervain M et al. The effect of low-level laser in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. Photomed Laser Surg 2009; 27(4):577-84.

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Jang H, Lee H. Meta-analysis of pain relief effects by laser irradiation on joint areas. Photomed Laser Surg 2012; 30(8):405-17.

Konstantinovic LM, Cutovic MR, Milovanovic AN et al. Low-level laser therapy for acute neck pain with radiculopathy: a double-blind placebo-controlled randomized study. Pain Med 2010; 11(8):1169-78.

Konstantinovic LM, Kanjuh ZM, Milovanovic AN et al. Acute low back pain with radiculopathy: a double-blind, randomized, placebo-controlled study. Photomed Laser Surg 2010; 28(4):553-60.

Kiritsi O, Tsitas K, Malliaropoulos N et al. Ultrasonographic evaluation of plantar fasciitis after low-level laser therapy: results of a double-blind, randomized, placebo-controlled trial. Lasers Med Sci 2010; 25(2):275-81.

Marini I, Gatto MR, Bonetti GA. Effects of superpulsed low-level laser therapy on temporomandibular joint pain. Clin J Pain 2010; 26(7):611-6

Matsutani LA, Marques AP, Ferreira EA et al. Effectiveness of muscle stretching exercises with and without laser therapy at tender points for patients with fibromyalgia. Clin Exp Rheumatol 2007; 25(3):410-5.

Meireles SM, Jones A, Jennings F et al. Assessment of the effectiveness of low-level laser therapy on the hands of patients with rheumatoid arthritis: a randomized double-blind controlled trial. Clin Rheumatol 2010; 29(5):501-9

Migliorati C, Hewson I, Lalla RV et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 2013 Jan;21(1):333-41.

Mosby's Medical, Nursing, & Allied Health Dictionary, 6th edition.

Omar MTA, Ebid AA, El Morsy AM. Treatment of post-mastectomy lymphedema with laser therapy: double blind placebo control randomized study. J Surg Res 2011; 165(1):82-90

Omar MT, Shaheen AA, Zafar H. A systematic review of the effect of low-level laser therapy in the management of breast cancer-related lymphedema. Support Care Cancer 2012; 20:2977-84

Oton-Leite AF, Correa de Castro AC, Morais MO et al. Effect of intraoral low-level laser therapy on quality of life of patients with head and neck cancer undergoing radiotherapy. Head Neck 2012; 34(3):398-404.

Petrucci A, Sgolastra F, Gatto R et al. Effectiveness of low-level laser therapy in temporomandibular disorders: a systematic review and meta-analysis. J Orofac Pain 2011; 25(4):298-307

Rayegani S, Bahrami M, Samadi B et al. Comparison of the effects of low energy laser and ultrasound in treatment of shoulder myofascial pain syndrome: a randomized single-blinded clinical trial. Eur J Phys Rehabil Med 2011; 47(3):381-9

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Savigny P, Kuntze S, Watson P et al. Low back pain: early management of persistent non-specific low back pain. National Collaborating Centre for Primary Care and Royal College of General Practitioners. May 2009. [Website]:

<http://www.nice.org.uk/nicemedia/live/11887/44343/44343.pdf>. Accessed July 31, 2013.

Schubert MM, Eduardo FP, Guthrie KA et al. A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation. Support Care Cancer 2007; 15(10):1145-54

Shooshtari SM, Badiie V, Taghizadeh SH et al. The effects of low level laser in clinical outcome and neurophysiological results of carpal tunnel syndrome. Electromyogr Clin Neurophysiol 2008; 48(5):229-31.

Stergioulas A, Stergioula M, Aarskog R et al. Effects of low-level laser therapy and eccentric exercises in the treatment of recreational athletes with chronic Achilles tendinopathy. Am J Sports Med 2008; 36(5):881-7.

Stergioulas A. Low-power laser treatment in patients with frozen shoulder: preliminary results. Photomed Laser Surg 2008; 26(2):99-105.

Tascioglu F, Degirmenci NA, Ozkan S et al. Low-level laser in the treatment of carpal tunnel syndrome: clinical, electrophysiological, and ultrasonographical evaluation. Rheumatol Int 2012; 32(2):409-15.

Tumilty S, McDonough S, Hurley DA et al. Clinical effectiveness of low-level laser therapy as an adjunct to eccentric exercise for the treatment of Achilles' tendinopathy: a randomized controlled trial. Arch Phys Med Rehabil 2012; 93(5):733-9.

Tumilty S, Munn J, McDonough S et al. Low level laser treatment of tendinopathy: a systematic review with meta-analysis. Photomed Laser Surg 2010, 28(1):3-16.

U.S. Food and Drug Administration. 510(k) Summary: MicroLight 830. 2002

Venezian GC, da Silva MA, Mazzetto RG et al. Low level laser effects on pain to palpation and electromyographic activity in TMD patients: a double-blind, randomized, placebo-controlled study. Cranio 2010; 28(2):84-91.

Yeldan I, Cetin E, Ozdincler AR. The effectiveness of low-level laser therapy on shoulder function in subacromial impingement syndrome. Disabil Rehabil 2009; 31(11):935-40.

Yousefi-Nooraie R, Schonstein E, Heidari K et al. Low level laser therapy for nonspecific low-back pain. Cochrane Database Syst Rev 2008; (2):CD005107.

High power Class IV Therapeutic Laser Light Therapy

MEDICAL POLICY



POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

Avicenna. Medical Professionals, Product Overview, Avicenna Laser Technology's HP-7.5 Class IV Therapeutic Laser. [Website]: <http://avicennalaser.com/class-iv-high-power-laser.htm> Accessed July 31, 2013.

Wertz RL. Class IV "high-power" laser therapy in chiropractic and rehabilitation. Chiroweb. Dynamic Chiropractic 2006; 24: 23. [Website]: <http://www.chiroweb.com/archives/24/23/02.html>. Accessed July 31, 2013.

VIII. CODING INFORMATION

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Investigational, and therefore not covered, when used to report transcutaneous laser therapy:

CPT Codes ®							
97026							

Current Procedural Terminology (CPT) copyrighted by American Medical Association. All Rights Reserved.

Investigational, and therefore not covered:

HCPCS Code	Description
S8948	APPLIC MODAL 1/MORE AREAS; LW-LEVL LASR; EA 15 M

The following ICD-10 diagnosis codes will be effective October 1, 2014

ICD-10-CM Diagnosis Code*	Description
	Investigational for all diagnoses

MEDICAL POLICY



POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

G56.0-G56.02	Carpal tunnel syndrome
L98.411-L98.499	Non-pressure chronic ulcer of skin, not elsewhere classified, code range
M05.00-M05.9	Rheumatoid arthritis with rheumatoid factor code range
M06.00-M06.9	Other rheumatoid arthritis code range
M17.0-M17.9	Osteoarthritis of knee code range
M25.521-M25.529	Pain in elbow code range
M26.60-M26.69	Temporomandibular joint disorders code range
M54.5	Low back pain
M75.40-M75.42	Impingement syndrome of shoulder code range
M76.60-M76.72	Achilles tendinitis code range
M79.7	Fibromyalgia

*If applicable, please see Medicare LCD or NCD for additional covered diagnoses.

IX. POLICY HISTORY

MP-1.097	CAC 10/28/03
	CAC 5/31/05
	CAC 2/28/06
	CAC 2/27/07
	CAC 1/29/08
	CAC 1/27/09
	CAC 1/26/10 Consensus review.
	CAC 4/26/11 Consensus review.

MEDICAL POLICY

POLICY TITLE	TRANSCUTANEOUS LASER THERAPY
POLICY NUMBER	MP- 1.097

	CAC 6/26/12 Consensus review. BCBSA Background/Description adopted for low-level laser therapy. No change to policy statements, references updated.
	7/26/13 Admin coding review complete--rsb
	CAC 9/24/13 Consensus review. No change to policy statements. References updated.

Health care benefit programs issued or administered by Capital BlueCross and/or its subsidiaries, Capital Advantage Insurance Company®, Capital Advantage Assurance Company® and Keystone Health Plan® Central. Independent licensees of the BlueCross BlueShield Association. Communications issued by Capital BlueCross in its capacity as administrator of programs and provider relations for all companies